Sanofi-Aventis reports results from atrial fibrillation trial
According to the company, dronedarone showed a decrease of safety events versus amiodarone but more occurrences of the composite primary endpoint. There were 184 patients (73.9%) who reached
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.